Cemiplimab with or without fianlimab after Y90 for liver cancer
Part of Cancer, Digestive system clinical trials.
This trial tests adding two immunotherapy drugs (cemiplimab and fianlimab) after a standard liver cancer treatment called Y90 radioembolization. It aims to see if combining these therapies can better control the cancer.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have been diagnosed with liver cancer (hepatocellular carcinoma).
- You are eligible for Y90 treatment, which means your lungs can safely handle the dose and enough healthy liver will remain.
- You are 18 years or older.
- Your liver function is good enough (Child-Pugh score A to B7).
- You have not had more than one prior liver-directed treatment like TACE or Y90.
- You have not had any prior systemic therapy (medication taken by mouth or through a vein) for liver cancer.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether combining an immunotherapy drug with a special type of liver radiation (yttrium-90) can control metastatic hepatocellular carcinoma (liver cancer that has spread). It may help by boosting your immune system and shrinking liver tumors at the same time.
This trial tests combining Yttrium-90 microspheres (tiny radioactive beads delivered into the liver), immunotherapy (drugs that help your immune system fight cancer), and anti-angiogenesis drugs (medicines that block blood supply to tumors) followed by a liver-directed chemotherapy infusion. It is designed for people with hepatocellular carcinoma (liver cancer) that cannot be removed with surgery yet may become operable after this treatment.
This trial tests a combination of two drugs (atezolizumab and bevacizumab) plus a targeted radiation treatment (Y-90 radioembolization) for people with liver cancer who are waiting for a liver transplant. The goal is to see if this treatment can help control the cancer and improve transplant outcomes.
This Phase 2 trial tests TheraSphere® (a Y-90 radiation treatment delivered to the liver) combined with standard systemic therapy in people with high-risk hepatocellular carcinoma (HCC). It aims to shrink tumors and improve outcomes for people whose liver cancer is at higher risk to worsen.
This trial tests a new immunotherapy combination for older patients with a specific type of colorectal cancer that has not been treated before. The goal is to see if these drugs can help the immune system fight the cancer without needing surgery or standard chemotherapy.
This trial tests a combination of a drug called cemiplimab (an immunotherapy that helps your immune system fight cancer) and a type of targeted radiation (Y-90 SIR-Spheres) given directly to liver tumors. It is for people with breast cancer that has spread to the liver and who have already had at least one type of chemotherapy.
Hear when a new Hepatocellular Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.